100960-16-5

Basic information

• Product Name: 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI)
• Synonyms: 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI);2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester;Ethyl 4-(chloromethyl)thiazole-2-carboxylate
• CAS NO: 100960-16-5
• Molecular Formula: C₇H₈ClNO₂S
• Molecular Weight: 205.664
• Product Categories: THIAZOLE
• Mol File: 100960-16-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 55-56 °C
• Boiling Point: 303.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.333±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.73±0.10(Predicted)
• CAS DataBase Reference: 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI)(100960-16-5)
• EPA Substance Registry System: 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI)(100960-16-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 100960-16-5(Hazardous Substances Data)

Usage

General Description

2-Thiazolecarboxylic acid, 4-(chloromethyl)-, ethyl ester is a chemical compound with the molecular formula C9H9ClN2O2S. It is an ethyl ester derivative of a thiazole carboxylic acid, and it contains a chloromethyl group. 2-Thiazolecarboxylicacid,4-(chloromethyl)-,ethylester(6CI,9CI) is used in the synthesis of various pharmaceuticals and agrochemicals. It has potential applications as an intermediate in the production of insecticides, fungicides, and other biologically active compounds. Additionally, it can be used as a building block in the development of new materials and chemical products. However, it is important to handle and use this chemical with care, as it may have hazardous properties and should be handled in accordance with safety guidelines and regulations.

Upstream product

• 86563-22-6 Thioxamidsaeure-methylester 
• 534-07-6 1,3-Dichloroacetone 
• 51216-90-1 ethyl 2-thiooxamate 
• 16982-21-1 ethyl 2-amino-2-thioxoacetate 

Downstream Products

• 1381778-52-4 N-(2-((2-(methoxymethyl)thiazol-4-yl)methyl)-2H-1,2,3-triazol-4-yl)-5-phenyloxazole-4-carboxamide 
• 349655-00-1 ethyl 4-(diphenylphosphinoylmethyl)thiazole-2-carboxylate 
• 200418-16-2 4-Chloromethyl-thiazole-2-carbonyl chloride 

Relevant articles and documents

Sulfur-containing compound based on glutaryl imide skeleton and application of compound

The present disclosure relates to compound shown in a formula (I) or salts, solvates, isotope-enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers of the compound, andthe application thereof in the treatment of tumours. The present disclosure also provides tumor treatment application of the compound showed in a formula (I') or pharmaceutically acceptable salts, solvates, isotope-enriched analogs, tautomers, polymorphic substances, stereoisomers, or mixtures of stereoisomers of the compound.

Structure-Activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating mycobacterium tuberculosis

Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 μM, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 μM concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.

Biaryloxymethylarenecarboxylic acids as glycogen synthase activator

The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, m, n, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases that are associated with the activation of the glycogen synthase enzyme, such as diabetes.